InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 |
|---|---|---|
| Clinical treatment programs – US | $88K-48.2% | $170K |
| Total Revenues | $88K-48.2% | $170K |
| Production costs | $128K+312.9% | $31K |
| Research and development | $3.9M-36.7% | $6.2M |
| General and administrative | $7.7M-43.9% | $13.7M |
| Total Costs and Expenses | $11.8M-41.1% | $19.9M |
| Operating loss | -$11.7M+41.0% | -$19.8M |
| (Loss) gain on investments | $17K+118.3% | -$93K |
| Interest and other income | $3.2M-38.7% | $5.2M |
| Interest expense | -$812K-38.8% | -$585K |
| Issuance cost | -$433K | — |
| Loss on warrant issuance | -$4.0M | — |
| Change in fair value of warrants | -$272K+40.6% | -$458K |
| Loss from sale of income tax operating losses | -$1.6M | — |
| Net Loss | -$14.0M+19.4% | -$17.3M |
| Basic loss per share | -$9K+72.1% | -$31K |
| Diluted loss per share | -$9K+72.1% | -$31K |
| Weighted average shares outstanding basic | $1.62B+189.0% | $560.2M |
| Weighted average shares outstanding diluted | $1.62B+189.0% | $560.2M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer